Skip to content

Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery

Analgesic Efficiency of the Type 3 Quadratum Lumborum Block in Patients Undergoing Total Hip Arthroplasty : a Randomized Double Blinded Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04555291
Acronym
QLB-3
Enrollment
60
Registered
2020-09-18
Start date
2022-01-05
Completion date
2024-10-10
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty

Brief summary

Total hip arthroplasty (THA) is one of the main elective orthopedic surgery. Recent studies have proven that patients undergoing an elective THA who are part of a fast track surgery program including an opioid free anesthesia (OFA) presented a decrease of mortality and a reduced in-hospital length of stay. Based on the anatomical knowledges, the Quadratus Lumborum Block seems to be an interesting locoregional technique for patients undergoing THA. So far, there is no recommanded locoregional aesthesia in this indication. The investigators hypothezised that QLB would give an efficient analgesia in the 24h following a THA. Therefor, the study performed a prospective, randomized, double blind trial in the Nice Universitary hospital of Pasteur 2 and in Arnault Tzanck Institute among all patients who underwent THA, comparing a QLB using ropivacaïne 2mg/ml 20ml vs isotonic saline solution 20 ml.The main end-point is the decrease opiod consumption in the 24h following THA.

Interventions

DRUGRopivacaine injection

Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml

OTHERNACL

Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• All adult patients with unilateral programmed total hip prosthesis surgery are included in the absence of inclusion criteria. * Obligation for all patients to be affiliated with social security * Patient Informed Consent Signature

Exclusion criteria

* chronic opiod consumption * pregnancy * mental disorder that prevents the usage of the numeric analog scale * Contra indications of the realization of QLB * Local infection * Allergic to the local anesthesia * Hemostasis disorder * Incapacity of giving the consent : individuals under guardianship by court order, or under judicial protection

Design outcomes

Primary

MeasureTime frameDescription
Opoïd consumptionAt 24 HoursThe main end point of this study is the decrease of opiod consumption in the 24h following THA.

Secondary

MeasureTime frameDescription
morphine equivalent doseAt 48 Hoursfollowing surgery at rest and in motion

Countries

France

Contacts

PRINCIPAL_INVESTIGATORRozier Romain

Anesthésie Réanimation - CHU de Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026